Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defactinib or Avutometinib in Glioblastoma
NCT05798507Phase 1Active, not recruiting
- Sponsor
- Emory University
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of defactinib and avutometinib in glioblastoma (GBM) (2 arms), sponsored by Emory University. Primary endpoints: Concentration of defactinib that accumulates in the glioblastoma (GBM) and brain around tumor, Concentration of avutometinib (VS-6766) that accumulates in the GBM and brain around tumor and 2 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
defactinibavutometinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05798507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798507.